Founded in 2006, Oramed Pharmaceuticals Inc. (ORMP) is a game-changer in the pharmaceutical industry with its ground-breaking technology in the oral administration of medications. This pharmaceutical company is based in Jerusalem, Israel, specializing in the research and development of innovative drugs that were traditionally available only via injection. A publicly-traded company listed on the NASDAQ, Oramed is on a mission to introduce revolutionary solutions to improve the quality of life of millions of people across the globe.
This pioneer biopharmaceutical company has successfully developed an Oral Insulin Capsule, which holds the potential to transform the treatment approach for millions of diabetics worldwide. Oramed's work is focused on the use of Protein Oral Delivery technology (POD), which emerged from more than 30 years of research at the Jerusalem Hadassah-Hebrew University Medical Centre. Unlike insulin injections, oral insulin imitates insulin's natural location and timing in the body, leading to better metabolic regulation and causing fewer side effects.
Additionally, the potential of Oramed's technology also extends to treating other diseases, such as the oral administration of GLP-1 analogs. These developments play a significant role in the healthcare sector, as they offer a comfortable, cost-effective, and more efficient way for patients to consume their medication. Moreover, Oramed's technological advancement is essential especially for patients who require regular medication, eliminating the discomfort of using injection-based drugs.
Looking ahead, Oramed’s exceptional achievements have led to the creation of Oravax Medical Inc., a joint venture with Premas Biotech. The primary objective is to develop a novel oral COVID-19 vaccine which will be a massive breakthrough in the fight against the pandemic, given the advantages of oral vaccines with their simple and efficient method of administration.
In 2022, Oramed Pharmaceuticals announced ground-breaking preliminary results of the Phase 3 ORA-D-013-1 oral insulin study, marking a historic milestone in making oral insulin a reality to improve the lives of people with diabetes around the world.
Overall, Oramed Pharmaceuticals Inc. represents a unique blend of technological innovation, and medical expertise, guided by a robust commitment to research and development, creating an improved and convenient treatment method for patients. Their pioneering work is an outstanding contribution to the world of medicine and a breakthrough in drug delivery technology.